Table 1 Summary of sample characteristics by two data sources

Age (years, Mean ± SD)

61.72 ± 12.26

–

–

–

59.55 ± 12.34

63.76 ± 11.95)

.09

 65 years old

54 (55.67%)

30 (63.83%)

24 (48%)

.11

 \(\ge 65\) years old

43 (44.33%)

17 (36.17%)

26 (52%)

Gender

.91

.05

 Female

48 (49.48%)

27 (50.0%)

21 (48.8%)

28 (59.57%)

20 (40%)

 Male

49 (50.52%)

27 (50.0%)

22 (51.2%)

19 (40.43%)

30 (60%)

Race

.02

.78

 White

83 (85.57%)

42 (50.6%)

41 (95.3%)

39 (82.98%)

44 (88%)

 Non-White

14 (14.4%)

12 (22.2%)

2 (4.7%)

8 (17.02%)

6 (12%)

Types of Cancer

.13

 < .001

 Breast

15 (15.46%)

9 (16.7%)

6 (14.0%)

15 (31.91%)

0 (0%)

 Colorectal

18 (18.56%)

14 (25.9%)

4 (9.3%)

9 (19.15%)

9 (18%)

 Pancreatic

40 (41.24%)

18 (33.3%)

22 (51.2%)

9 (19.15%)

31 (62%)

 Others

24 (24.74%)

13 (24.1%)

11 (25.6%)

14 (29.79%)

10 (20%)

Stage of Cancer

.26

.002

 Non-Advanced/metastatic

40 (41.24%)

25 (46.3%)

15 (34.9%)

12 (25.53%)

28 (56%)

 Advanced/metastatic

57 (58.76%)

29 (53.7%)

28 (65.1%)

35 (74.47%)

22 (44%)

Treatment type

.52

.04

 Monotherapy

28 (28.87%)

17 (31.5%)

11 (25.6%)

18(38.30%)

10 (20%)

 Combination therapy

69 (71.13%)

37 (68.5%)

32 (74.4%)

29 (61.70%)

40 (80%)

 Capecitabine daily dose (mg) (Mean ± SD)

2459.38 ± 1053.07

2709.4 ± 1053.24

2151.2 ± 979.2

.009

2621.74 ± 989.71

2310.00 ± 1096.79

.21

 Days on treatment (days) (Mean ± SD)

49.76 ± 77.83

42.5 ± 60.6

58.9 ± 95.2

.33

52 ± 99.53

47.66 ± 50.60

.003

Cycle pattern

.24

 < .001

 Continuous

3 (3.12%)

1 (1.9%)

2 (4.7%)

0 (0%)

3 (6%)

 7 days on, 7 days off

9 (9.38%)

5 (9.3%)

4 (9.3%)

0 (0%)

9 (18%)

 14 days on, 14 days off

5 (5.21%)

5 (9.3%)

0 (0.0%)

3 (6.52%)

2 (4%)

 14 days on, 7 days off

62 (64.58%)

32 (59.3%)

30 (69.8%)

30 (65.22%)

32 (64%)

 21 days on, 7 days off

4 (4.17%)

1 (1.9%)

3 (7.0%)

0 (0%)

4 (8%)

 Others

7 (7.29%)

5 (9.3%)

2 (4.7%)

7 (15.22%)

0 (0%)

Number of comorbidities (Mean ± SD)

3.90 ± 2.31,

range 1–12

3.93 ± 2.12,

range 1–12

3.86 ± 2.57,

range 1–10

.89

5.40 ± 2.41,

range 1–21

2.48 ± 0.89,

range 1–4

 < .001

Number of outpatient medications (Mean ± SD, range)

10.14 ± 5.19,

range 1–28

9.02 ± 5.34, range 1–28

11.56 ± 4.67, range 2–23

.01

8.15 ± 5.34,

range 1–28

12.02 ± 4.31,

range 4–23

 < .001

Nausea

44 (45.4%)

28 (51.9%)

16 (37.2%)

.15

22 (46.8%)

22 (44.0%)

.78

Vomiting

19 (19.6%)

14 (25.9%)

5 (11.6%)

.08

9 (19.1%)

10 (20.0%)

.92

Diarrhea

48 (49.5%)

26 (48.1%)

22 (51.2%)

.77

16 (34.0%)

32 (64.0%)

.003

HFS

29 (29.9%)

12 (22.2%)

17 (39.5%)

.06

11 (23.4%)

18 (36.0%)

.18

Fatigue

67 (69.1%)

30 (50.6%)

37 (86.0%)

.001

24 (51.1%)

43 (86.0%)

 < .001

Constipation

34 (35.1%)

17 (31.5%)

17 (39.5%)

.41

9 (19.1%)

25 (50.0%)

.001

Mouth sores

19 (19.8%)

7 (13.0%)

12 (27.9%)

.07

6 (12.8%)

13 26.0%)

.10

Sleep difficulties

25 (25.8%)

15 (27.8%)

10 (23.3%)

.61

1 ((2.1%)

24 (48.0%)

 < .001

Dose reduction (yes)

16 (16.49%)

7 (13.0%)

9 (20.9%)

.41

12 (25.53%)

4 (8%)

.02

Dose interruption (yes)

29 (29.90%)

15 (27.8%)

14 (32.6%)

.61

15 (31.91%)

14 (28%)

.67